Pharmacokinetics and the Most Suitable Regimen of Panipenem/Beta Mipron in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study

Critically ill patients often have complications of acute renal failure induced by severe infection or sepsis. The patients need administration of broad-spectrum antibiotics as well as continuous renal replacement therapy (CRRT). However, there is no uniform pharmacokinetics of antibiotics during the CRRT because CRRT is performed with the various combinations of dialysate flows (QD) and ultrafiltrate flows (QF). The aims of this study were to estimate the pharmacokinetics of panipenem/beta Mipron (PAPM/BP) and to determine the appropriate treatment regimens for PAPM/BP in critically ill patients undergoing CRRT. In patients with CRRT, the PAPM total clearance (PAPM CLtot) was calculated as the sum of PAPM clearance dependent on the living body and CRRT and shown as follows: PAPM CLtot (ml/min) = (1.2 CLcre + 66.5) + 0.86 (QD + QF) where CLcre is creatinine clearance. Pharmacokinetic values of PAPM were measured in 4 patients with CRRT. According to these results, the most appropriate treatment regimen regarding PAPM CLtot (ml/min) showed as follows: PAPM CLtot < 80 0.5 g every 12 hours or 1 g every 15 hours PAPM CLtot 80 to 120 0.5 g every 8 hours or 1 g every 12 hours PAPM CLtot 120 to 160 0.5 g every 6 hours or 1 g every 8 hours.

[1]  H. Goossens,et al.  Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programme. , 2004, International journal of antimicrobial agents.

[2]  R. Bellomo,et al.  High-volume haemofiltration in human septic shock , 2001, Intensive Care Medicine.

[3]  Rinaldo Bellomo,et al.  Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial , 2000, The Lancet.

[4]  R. Beale,et al.  Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno‐venous hemofiltration or hemodiafiltration , 2000, Critical care medicine.

[5]  J. Donauer,et al.  Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. , 1999, Kidney international. Supplement.

[6]  C. Ronco,et al.  CRRT efficiency and efficacy in relation to solute size. , 1999, Kidney international. Supplement.

[7]  T. Schroeder,et al.  Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration , 1998, Antimicrobial Agents and Chemotherapy.

[8]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[9]  K. Yamaguchi,et al.  Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released , 1999, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[10]  J. Shimada,et al.  Overview of a new carbapenem, panipenem/betamipron. , 1994, Drugs under experimental and clinical research.

[11]  M. Nakashima,et al.  PHASE I STUDY OF PANIPENEM/BETAMIPRON I:SINGLE DOSE STUDY , 1991 .

[12]  Y. Tanigawara,et al.  Nephroprotective effect and its mechanism of betamipron (1) —Relationships of renal transport— , 1991 .

[13]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.